Compass Pathways (NASDAQ:CMPS) Stock Bumped Up to Sell by Wall Street Zen

Wall Street Zen upgraded shares of Compass Pathways (NASDAQ:CMPS) from a strong sell rating to a sell rating in a report published on Sunday,Wall Street Zen reports.

Other equities research analysts also recently issued reports about the company. Jefferies Financial Group reiterated a “buy” rating on shares of Compass Pathways in a research report on Wednesday, September 9th. Morgan Stanley increased their price target on Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Wells Fargo & Company cut their price target on Compass Pathways from $13.00 to $10.00 and set an “equal weight” rating for the company in a report on Wednesday, November 4th. BTIG Research reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Compass Pathways in a research note on Tuesday, November 3rd. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Compass Pathways in a report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.14.

Compass Pathways Price Performance

Shares of CMPS stock opened at $8.61 on Friday. The stock has a market cap of $1.19 billion, a P/E ratio of -2.47 and a beta of 2.43. Compass Pathways has a 52 week low of $4.88 and a 52 week high of $15.87. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.35. The company’s fifty day simple moving average is $12.32 and its two-hundred day simple moving average is $10.41.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.08. Analysts predict that Compass Pathways will post -0.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Candriam S.C.A. raised its position in Compass Pathways by 18.6% during the third quarter. Candriam S.C.A. now owns 1,510,695 shares of the company’s stock valued at $18,862,000 after purchasing an additional 236,417 shares during the period. Eagle Health Investments LP lifted its stake in shares of Compass Pathways by 35.6% in the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock valued at $11,394,000 after purchasing an additional 541,039 shares during the last quarter. CenterBook Partners LP lifted its stake in shares of Compass Pathways by 454.1% in the 3rd quarter. CenterBook Partners LP now owns 695,943 shares of the company’s stock valued at $8,658,000 after purchasing an additional 570,349 shares during the last quarter. Orbimed Advisors LLC bought a new stake in shares of Compass Pathways in the 1st quarter valued at approximately $6,363,000. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Compass Pathways by 454.2% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock worth $6,130,000 after purchasing an additional 908,483 shares during the period. 46.19% of the stock is owned by hedge funds and other institutional investors.

About Compass Pathways

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.